Azitra (AZTR) vs CalciMedica (CALC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CalciMedica is the larger company by market cap ($8.9 million vs $8.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZTR | CALC |
|---|---|---|
| Share price | $0.132 | $1.30 |
| Market cap | $8.00M | $8.88M |
| 1-day change | 0.00% | -12.16% |
| YTD return | — | -96.05% |
| 1-year return | — | -91.84% |
| EPS (TTM) | $-0.28 | $-6.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.09 | $36.00 |
| 52-week low | $0.10 | $1.30 |
| Distance from 52-week high | -87.89% | -96.39% |
| Analyst consensus | buy | none |
| Avg. price target upside | +407.58% | +3746.15% |
| Average volume | 1.70M | 75.54K |
| Shares outstanding | 60.60M | 6.83M |
| Employees | 13 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Azitra
AZTR stock →Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S.
Healthcare · Biotechnology · 13 employees
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Healthcare · Biotechnology · 15 employees
AZTR vs CALC FAQ
Which is bigger, Azitra or CalciMedica?
CalciMedica (CALC) is larger, with a market capitalization of $8.88M compared with $8.00M for Azitra (AZTR).
Are Azitra and CalciMedica in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.